Once you decide to initiate oral treatment, what regimen, in what sequence and frequency of dosing, are currently recommended? What are the expected microbial conversion rates based on the patient’s underlying disease and other risk factors?

Once you decide to initiate oral treatment, what regimen, in what sequence and frequency of dosing, are currently recommended? What are the expected microbial conversion rates based on the patient’s underlying disease and other risk factors?

Once you decide to initiate oral treatment, what regimen, in what sequence and frequency of dosing, are currently recommended? Whatt are the expected microbial conversion rates based on the patient’s underlying disease and other risk factors?


Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | NTM-Pulmonary Infection Intelligence Zone

Presenter

Mehdi Mirsaeidi, MD, MPH

Mehdi Mirsaeidi, MD, MPH

Director of University of Miami and VA Sarcoidosis Programs
Co-Director UM NTM Program
IRB Vice-Chairman, Miami VA Healthcare System
Assistant Professor of Department of Medicine
Assistant Professor of Clinical Public Health Sciences
Division of Pulmonary